Q-omics provides the consensus-scored TMEM98 profile across patient tissues and cancer cell-line models. TMEM98 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEM98 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, TMEM98 RNA expression shows 18,917 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, KICH, and TGCT as cancer lineages where TMEM98 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM98 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM98 survival associations across molecular data types. TMEM98 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM98 RNA expression–survival associations across cancer types. High TMEM98 expression shows unfavorable associations in ACC, CESC and LIHC, but favorable associations in BRCA, LAML and THCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TMEM98 RNA expression.
This table summarizes TMEM98 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM98. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM98 shows lower tumor expression in KICH and LUSC and higher tumor expression in THCA, LIHC, CHOL and KIRC. The KICH box plot shows higher TMEM98 RNA expression in normal versus tumor tissue (log2 FC = −2.700, t-test p < 0.001).
This table shows molecular features associated with TMEM98 in patient tissues and cancer cell lines. In patient samples, TMEM98 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM98 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SKIN.
